Corrigendum to "Modelling the potential effectiveness of hepatitis C screening and treatment strategies during pregnancy in Egypt and Ukraine" [J Hepatol (2023) 937-946]
J Hepatol. 2024 Feb;80(2):379.
doi: 10.1016/j.jhep.2023.12.013.
Epub 2024 Jan 5.
1 Université Paris Cité and Université Sorbonne Paris Nord, Inserm, IAME, F-75018 Paris, France. Electronic address: nadia.hachicha@inserm.fr.
2 MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, London, UK.
3 Population Health Sciences, University of Bristol Medical School, Bristol, UK.
4 Department of Community, Environmental, and Occupational Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
5 Department of Paediatrics and the Clinical Research Center, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
6 MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, London, UK; Institute for Global Health, University College London, London, UK.
7 Département de Santé Publique/Pôle Référence Hépatite C, CHU Nice, Nice, France.
8 Department of Paediatric Infectious Diseases and Paediatric Immunology, Shupyk National Healthcare University of Ukraine, Kyiv, Ukraine.
9 Université Paris Cité and Université Sorbonne Paris Nord, Inserm, IAME, F-75018 Paris, France; Service de Maladies Infectieuses et Tropicales, Hôpital Bichat-Claude Bernard, F-75018 Paris, France.
10 Université Paris Cité and Université Sorbonne Paris Nord, Inserm, IAME, F-75018 Paris, France. Electronic address: sylvie.burban@inserm.fr.